FDA smacks Hospira with nearly 2 dozen observations at India plant

Eric Palmer

is getting on top of its manufacturing issues in the U.S. But the company continues to face issues at a  in  that received a warning letter in the spring. The FDA recently came back for a follow-up which turned up two .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS